Quelle: British Medical Journal

Verschiedene kleinere  wissenschaftliche Untersuchungen erbrachten in der Vergangenheit Hinweise darauf, dass die Hyposensibilisierung  bei Heuschnupfen (aufgrund einer Pollen- und Gräserallergie)  dann besonders gut anschlägt, wenn die Patienten zusätzlich das Enzym Beta-Glukoronidase  erhalten.

Jetzt zeigte eine im British Medical Journal veröffentlichte größere Studie, dass diese Therapie-Variante gegenüber der Standardtherapie keinerlei Vorteile hat.

BMJ 2003;327:251-254 (2 August)

Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study

Michael J Radcliffe, visiting clinical research fellow1, George T Lewith, senior clinical research fellow2, Richard G Turner, associate specialist in allergy3, Philip Prescott, professor of statistics4, Martin K Church, professor of immunopharmacology1, Stephen T Holgate, MRC clinical professor of immunopharmacology1

1 School of Medicine, Infection Inflammation and Repair Research Division, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, 2 School of Medicine, Community Clinical Sciences Research Division, University of Southampton, Royal South Hants Hospital, Southampton SO14 0YG, 3 North Hampshire Hospital, Basingstoke RG24 9NA, 4 Faculty of Mathematical Studies, University of Southampton, Southampton SO17 1BJ

Correspondence to: M J Radcliffe michael@radcliffe.net



Objective To assess the efficacy of enzyme potentiated desensitisation in the treatment of severe summer hay fever poorly controlled by pharmacotherapy.

Design Double blind randomised placebo controlled parallel group study.

Setting Hospital in Hampshire.

Participants 183 participants aged between 18 and 64 with a history of severe summer hay fever for at least two years; all were skin prick test positive to timothy grass pollen. 90 randomised to active treatment; 93 randomised to placebo.

Interventions Active treatment: two injections of enzyme potentiated desensitisation, given between eight and 11 weeks apart, each comprising 200 Fishman units of {beta} glucuronidase, 50 pg 1,3-cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract (pollen mixes for trees, grasses, and weeds; allergenic fungal spores; cat and dog danders; dust and storage mites) in a total volume of 0.05 ml of buffered saline. Placebo: two injections of 0.05 ml buffered saline solution.

Main outcome measures Proportion of problem-free days; global rhinoconjunctivitis quality of life scores assessed weekly during pollen season.

Results The active treatment group and the placebo group did not differ in the proportion of problem-free days, quality of life scores, symptom severity scores, change in quantitative skin prick provocation threshold, or change in conjunctival provocation threshold. No clinically significant adverse reactions occurred.

Conclusions Enzyme potentiated desensitisation showed no treatment effect in this study.

Volltext